News

ascopubs.org2d
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or ...
The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
ascopubs.org2d
Avelumab maintenance therapy for metastatic urothelial carcinoma: Efficacy analysis and sequential therapies from a multicentric oncology network.
Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey. This is an ASCO Meeting Abstract ...
UroToday5h
ASCO 2025: A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, Peposertib, and Avelumab in Advanced mCRPC: Phase I Results
Dr. Gay concluded his presentation discussing phase l results of a trial assessing radium-223, peposertib, and avelumab in advanced mCRPC with the following take home points: The combination of radium ...